Significantly Reduced Nasal Congestion, Polyp Size and Nearly Eliminated Need for Surgery Data Published in NEJM and Presented at AAAAI/WAO 2025 THOUSAND OAKS, Calif., March 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and AstraZeneca today announced full results from the Phase 3,...
Read More Details
Finally We wish PressBee provided you with enough information of ( POSITIVE RESULTS FROM TEZSPIRE® (TEZEPELUMAB-EKKO) PHASE 3 WAYPOINT TRIAL HIGHLIGHT RAPID, SUSTAINED EFFECT IN CHRONIC RHINOSINUSITIS WITH NASAL POLYPS )
Also on site :
- Drowning’s the No. 1 killer of young children — from Orange to Pasadena, experts are trying to change that
- 'Top Chef' Season 22 Episode 12 Elimination Results: Who Was Sent Home This Week?
- Hamas official says it rejects new US Gaza ceasefire plan backed by Israel